Med-IQ
Exploring the Clinical Potential of Home-Based Care After Hematopoietic Stem Cell Transplantation

Exploring the Clinical Potential of Home-Based Care After Hematopoietic Stem Cell Transplantation

Med-IQ Express
Continue to Course

Developed in collaboration
Med-IQ      Duke Medicine

Online Course | Specialties: Hematology, Oncology
Released: 1/31/2022
|
Expires: 1/30/2023
|
Max Credits: 0.25
Continue to Course Read Abstract

Faculty
Nelson Jen An Chao, MD
Donald D. and Elizabeth G. Cooke Professor
Chief of Division of Hematologic Malignancies and Cellular Therapy/BMT
Director of Global Cancer, Duke Cancer Institute
Professor of Medicine and Immunology
Research Professor of Global Health
Duke University School of Medicine
Durham, NC
  
Activity Planners
Amy Burdette, PhD
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD

Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Writer
Edward Allan Racela Sison, MD
Missouri City, TX
 
Learning Objective
Upon completion, participants should be able to:

  • Outline the rationale and potential clinical implications of the phase 2 study comparing home-based care to standard hospital care for patients who have received a stem cell transplant

Target Audience
This activity is intended for hematologist/oncologists and  hematology/oncology-focused nurse practitioners, physician assistants, and nurses.
 
Statement of Need
Hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy used to treat various high-risk malignant hematologic disorders, as well as several nonmalignant hematologic and genetic diseases. Despite increased use of and improved outcomes in HSCT, it remains a high-risk procedure, as complications related to transplant can cause significant morbidity and mortality. Infections are a common and significant sequela of HSCT, despite keeping patients in a protected environment during the pancytopenic phase. In addition, graft-versus-host disease is another common complication among patients undergoing HSCT. Patient quality of life is also significantly affected, particularly during the periods before and after transplant. The financial cost of HSCT is significant, with the hospital care accounting for the majority of expenses. One proposed approach for decreasing the financial burden of HSCT and improving quality of life and patient outcomes is using a home-based care model for the posttransplant period. As clinical trials investigate the home-based care model, hematology/oncology clinicians must stay up-to-date on these data so that they are prepared to implement practice-changing results into their clinic.

Collaboration Statement
This activity was developed by Med-IQ in collaboration with Duke Health.      

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: January 31, 2022
Expiration Date: January 30, 2023

Estimated Time to Complete This Activity: 15 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Nelson Jen An Chao, MD, has indicated no real or apparent conflicts.

Edward Allan Racela Sison, MD
Salary: Arcus Biosciences, Precision Medical Group
Ownership interest (stocks/stock options – excluding mutual funds): Arcus Biosciences, LabCorp, Moderna, UnitedHealth Group

The peer reviewers and other activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity. 

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-notice.

Complimentary CME
This activity is available free of charge to participants.
 
Copyright
© 2022 Duke University Health System

Abstract

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • HSCT is a potentially curative therapy used to treat various high-risk malignant hematologic disorders, as well as a number of nonmalignant hematologic and genetic diseases
  • Despite increased use of and improved outcomes in HSCT, it remains a high-risk procedure, as complications related to transplant are associated with significant morbidity, mortality, and high medical costs
  • One proposed approach for decreasing the financial burden of HSCT and improving quality of life and outcomes is using a home-based care model for the posttransplant period, with the understanding that the chosen approach must provide the ability to manage post-HSCT complications
  • Early clinical trials support using a home-based care model for posttransplant care
  • An ongoing phase 2 trial is seeking to determine whether home-based post-HSCT care will allow patients to maintain their normal bowel microbiota, thereby decreasing the risk of GVHD; secondary outcomes include nutritional status, the incidence of grade 2 to 4 acute GVHD, treatment-related morbidity and mortality, quality of life, and costs of care, all measured at 100 days post-HSCT

View reference list.

Click “Continue” to proceed through this activity and/or receive credit.

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.